Related Experiment Video
Updated: Jul 4, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
Published on: January 10, 2025
Is erythropoietin safe in haemodialysis patients with multiple myeloma ?
M Hussein1, J Mooij, H Roujouleh
1Department of Nephrology and Dialysis Al Hada Armed Forces Hospital, Taif, Saudi Arabia.
Abstract:
The use of recombinant human erythropoietin (rHuEpo) for the treatment of anemia of end-stage renal disease (ESRD) is now well established. There have also been reports about its use in treating the anemia of other diseases including multiple myeloma (MM). Some concern about the usage of rHuEpo in patients with MM has been raised by studies reporting worsening of myeloma activity after starting this drug. However, other studies have reported its safety in patients with MM. We report here a patient on maintenance haemodialysis, not known to have MM who developed symptoms related to this disease four months after starting rHuEpo. Although we might speculate that the onset of symptoms was coincidental and not causally related to rHuEpo, we recommend close monitoring of the disease activity in patients with MM receiving rHuEpo.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Erythropoiesis
Erythropoiesis
Hemodialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...